Brain Uptake Study of a New Imaging Tracer
Part of Brain & nervous system, Eyes & vision, Mental health clinical trials.
This study uses a special PET scan to see how a new tracer (18F-JSS20-183A) moves through the body and brain. It may help researchers learn more about brain diseases like Parkinson's and Alzheimer's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 40 and 85 years old.
- Have one of these conditions: progressive supranuclear palsy, corticobasal syndrome, multiple system atrophy, Parkinson's disease, frontotemporal lobar degeneration, Alzheimer's disease, or be a healthy volunteer.
- Not be pregnant or breastfeeding.
- No history of serious alcohol or drug abuse.
- Be able to have an MRI (no metal implants or devices that would make it unsafe).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special imaging tracer to see how it moves through the body and brain. It may help researchers understand brain changes in Parkinson's disease and related conditions.
This trial uses a special PET scan to see how a new imaging agent (called 11C-M503) travels through the body and brain. It may help researchers better understand brain conditions like Parkinson's disease.
This study uses brain imaging and tests to better understand Parkinson's disease and related conditions. It aims to improve diagnosis by comparing scans across different groups of people.
This trial uses a special imaging agent called [18F]NIDF to take pictures of tau protein clumps in the brain, which are linked to Alzheimer's and other memory or movement disorders. It may help doctors see these changes more clearly.
This study uses a special PET/CT brain scan to look at a protein called tau in people with memory/thinking and movement disorders. The results may help researchers understand how these diseases affect the brain and improve future diagnosis or care.
This Phase 3 study uses a PET/CT scan to measure whether a brain protein called tau (and related disease patterns) builds up in different dementia conditions. The goal is to better match which disorders have which brain changes and how they progress.
Hear when a new Tauopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.